A new report by visiongain forecasts that worldwide sales of human influenza vaccines will generate $6.4 billion in 2018. That sales growth will continue through to 2026, especially with the entrance of new industry players and advances in vaccine technology. That revenue prediction and others appear in Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026: Prospects for Technologies Including Trivalent and Quadrivalent Flu Shots, published in January 2016.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries in healthcare and other fields.

The new study analyses events, prospects and sales opportunities shaping the development, production and marketing of influenza vaccines from 2016. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials. That vaccines market holds many commercial opportunities from 2016 to 2026.

Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “We predict the influenza vaccines market will expand its revenues at a steady pace from 2016 to 2026. That progress will be stimulated by ageing populations and the increasing prevalence of chronic illnesses. Adding to this will be rising demand from emerging countries as their economies prosper and their healthcare expenditures rise.

“Our new study shows how the market share for countries can change owing to political and economic changes, and also through the emergence of new competitors in that industry. Furthermore, shifts in market share of submarkets are also shown, shedding light on future developments in influenza vaccine technology. Our study includes the next major breakthrough to transform the industry, the universal flu vaccine, which could provide immunity against all strains of influenza viruses.

“Prevalence of influenza rises globally. The most effective way to combat that widespread infection is through vaccination. As the world moves towards an ageing population, people’s susceptibility to the flu increases, raising demand for vaccines. Also improving healthcare systems, rising flu awareness and high birth rates in developing countries will stimulate demand for existing and new influenza vaccines from 2016. The human flu vaccination industry holds great potential for progress and high sales.”

Visiongain’s new investigation gives sales predictions for that market at overall world market, submarket, product and national level. It also explores research and development and gives qualitative analysis.

First that study gives revenue forecasts to 2026 for two submarkets:

• Trivalent vaccines
• Quadrivalent vaccines.

The new analysis also predicts revenues to 2026 for leading influenza vaccines:

• Fluzone/Vaxigrip
• Afluria/Fluvax
• Fluarix/FluLaval
• FluMist/Fluenz
• Fluvirin/Flucelvax
• FluBlok.

That report also shows prospects for influenza vaccine sales in developed and developing regions, with revenue forecasts to 2026 for 11 countries:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (the EU5 group)
• Brazil, Russia, India and China (the BRIC group).

And, in particular, the study explores these leading companies:

• Sanofi Pasteur
• GSK
• Novartis
• AstraZeneca
• CSL and Seqirus
• Protein Sciences Corporation.

Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).